SAN MATEO, Calif., Feb. 8, 2011 /PRNewswire/ — NeurogesX, Inc.
(Nasdaq:
NGSX), a biopharmaceutical company focused on developing and
commercializing novel pain management therapies, announced today
that Anthony DiTonno, President and Chief Executive Officer, is
scheduled to present at two upcoming conferences in New York, New
York: the 13th Annual BIO CEO & Investor Conference, to be held
February 14-15, 2011 at the Waldorf-Astoria Hotel; and the Leerink
Swann Hot Topics in Therapeutics Roundtable Conference, to be held
February 16-17, 2011 at The Roosevelt Hotel.
During the Leerink Swann Conference, Mr. DiTonno will also
represent NeurogesX on a panel of executives from leading
neurology/pain companies. Mr. DiTonno and Stephen Ghiglieri, SVP,
COO and CFO, will be available to respond to questions and to
participate in one-on-one meetings with investors attending both
conferences.Event: 13th Annual BIO CEO & Investor
ConferenceDate: Tuesday, February 15, 2011Time: 11:00 am ETPlace:
The Waldorf-Astoria Hotel, New York, NY (Conrad Room, 4th floor)
Event: Leerink Swann Hot Topics in Therapeutics Roundtable
ConferenceDate: Thursday, February 17, 2011Time: 11:00 am ET
(Neuro/Pain panel); 3:40 pm ET (presentation)Place: The Roosevelt
Hotel, New York, NY (Terrace Ballroom, lobby level) Both
presentations will be webcast live and archived for 90 days on the
investor relations section of NeurogesX’ website at www.neurogesx.com.
About NeurogesX, Inc. NeurogesX, Inc. (Nasdaq:
NGSX) is a San Francisco Bay Area-based biopharmaceutical
company focused on developing and commercializing novel pain
management therapies. NeurogesX was founded on the concept that use
of prescription-strength capsaicin could help manage the
‘/>”/>
